By G HossainPosted on February 2, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031. Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA Post navigation Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy QuestionsGSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data